Skip to content

Study · Non-randomized trial · n = 238 · 2025

5 results

[Cerebrolysin and the optimal timing of anticoagulation resumption in stroke: combined post hoc survival analysis of the CEREHETIS trial].

Kalinin MN, Khasanova DR

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2025Cited by 2 (Europe PMC)

PMID40123141 (opens in a new tab)DOI10.17116/jnevro202512503277 (opens in a new tab)PepBankPUB-40123141
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In stroke patients, Cerebrolysin reduced symptomatic hemorrhagic transformation risk versus thrombolysis and standard care alone.

    In plain wordsIn stroke patients, Cerebrolysin reduced symptomatic hemorrhagic transformation risk versus thrombolysis and standard care alone.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSymptomatic hemorrhagic transformation
    Study

    n = 238

    Comparator
    Intravenous thrombolysis and standard care without Cerebrolysin
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.245
    Cerebrolysin versus control
    95% confidence interval for symptomatic hemorrhagic transformation hazard ratio
    0.072 to 0.837
    Cerebrolysin with IVT and standard care versus IVT and standard care alone
    P value for symptomatic hemorrhagic transformation risk
    0.02
    Cerebrolysin with IVT and standard care versus IVT and standard care alone

    Source sentences

    Summary
    Cerebrolysin significantly reduced risk of symptomatic HT (HR 0.245; 95% CI 0.072-0.837; p=0.02) and any HT (HR 0.543; 95% CI 0.297-0.991; p=0.032).
    3 context sentences
    Summary · context
    A post hoc survival analysis of the CEREHETIS trial (ISRCTN87656744) included patients with middle cerebral artery infarctions.
    Summary · context
    The intervention group (IG, n=91) received Cerebrolysin with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=147) received IVT and standard care alone.
    Summary · context
    Additionally, a validation cohort (VC, n=248) from an observational study was analyzed.
  2. 02HumanNon-randomized trialSafety outcome

    In stroke patients, Cerebrolysin reduced any hemorrhagic transformation risk versus thrombolysis and standard care alone.

    In plain wordsIn stroke patients, Cerebrolysin reduced any hemorrhagic transformation risk versus thrombolysis and standard care alone.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseAny hemorrhagic transformation
    Study

    n = 238

    Comparator
    Intravenous thrombolysis and standard care without Cerebrolysin
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.543
    Cerebrolysin versus control
    95% confidence interval for any hemorrhagic transformation hazard ratio
    0.297 to 0.991
    Cerebrolysin with IVT and standard care versus IVT and standard care alone
    P value for any hemorrhagic transformation risk
    0.032
    Cerebrolysin with IVT and standard care versus IVT and standard care alone

    Source sentences

    Summary
    Cerebrolysin significantly reduced risk of symptomatic HT (HR 0.245; 95% CI 0.072-0.837; p=0.02) and any HT (HR 0.543; 95% CI 0.297-0.991; p=0.032).
    3 context sentences
    Summary · context
    A post hoc survival analysis of the CEREHETIS trial (ISRCTN87656744) included patients with middle cerebral artery infarctions.
    Summary · context
    The intervention group (IG, n=91) received Cerebrolysin with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=147) received IVT and standard care alone.
    Summary · context
    Additionally, a validation cohort (VC, n=248) from an observational study was analyzed.
  3. 03HumanNon-randomized trialMechanism

    In high-risk stroke patients (HTI=1-4), Cerebrolysin mitigated the compounding effect on hemorrhagic transformation hazard.

    In plain wordsIn high-risk stroke patients, Cerebrolysin reduced the compounding effect on bleeding hazard.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseCompounding effect in high-risk patients
    Study

    n: not reported in source

    Comparator
    Control and validation cohorts
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In high-risk patients (HTI=1-4), Cerebrolysin mitigated the compounding effect and reduced hazard levels to the threshold by day 2, compared to days 3-5 in the CG and VC.
    3 context sentences
    Summary · context
    A post hoc survival analysis of the CEREHETIS trial (ISRCTN87656744) included patients with middle cerebral artery infarctions.
    Summary · context
    The intervention group (IG, n=91) received Cerebrolysin with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=147) received IVT and standard care alone.
    Summary · context
    Additionally, a validation cohort (VC, n=248) from an observational study was analyzed.
  4. 04HumanNon-randomized trialSafety outcome

    In high-risk stroke patients (HTI=1-4), Cerebrolysin reduced hazard levels to the threshold by day 2, compared with days 3-5 in the control group and validation cohort.

    In plain wordsIn high-risk stroke patients, hazard fell to the threshold by day 2 with Cerebrolysin, compared with days 3-5 in the control and validation groups.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseTime to hazard threshold
    Study

    n: not reported in source

    Comparator
    Control group (IVT and standard care alone) and validation cohort
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Time to hemorrhagic transformation hazard threshold
    2 days
    High-risk patients (HTI=1-4); Cerebrolysin
    Time to hemorrhagic transformation hazard threshold
    3 to 5 days
    High-risk patients (HTI=1-4); control group and validation cohort

    Source sentences

    Summary
    In high-risk patients (HTI=1-4), Cerebrolysin mitigated the compounding effect and reduced hazard levels to the threshold by day 2, compared to days 3-5 in the CG and VC.
    3 context sentences
    Summary · context
    A post hoc survival analysis of the CEREHETIS trial (ISRCTN87656744) included patients with middle cerebral artery infarctions.
    Summary · context
    The intervention group (IG, n=91) received Cerebrolysin with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=147) received IVT and standard care alone.
    Summary · context
    Additionally, a validation cohort (VC, n=248) from an observational study was analyzed.
  5. 05HumanNon-randomized trialSafety outcome

    In low-risk stroke patients, Cerebrolysin had no measurable impact on hemorrhagic transformation.

    In plain wordsIn low-risk stroke patients, Cerebrolysin had no measurable impact on hemorrhagic transformation.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeHemorrhagic transformation in low-risk patients
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In low-risk patients (HTI=0), hazard levels remained below the threshold from day 1, with no measurable impact of Cerebrolysin on HT.
    3 context sentences
    Summary · context
    A post hoc survival analysis of the CEREHETIS trial (ISRCTN87656744) included patients with middle cerebral artery infarctions.
    Summary · context
    The intervention group (IG, n=91) received Cerebrolysin with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=147) received IVT and standard care alone.
    Summary · context
    Additionally, a validation cohort (VC, n=248) from an observational study was analyzed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.